Show pageBacklinksCite current pageExport to PDFBack to top This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong. Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic medication, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved by the U.S. Food and Drug Administration (FDA) on January 25, 2008, and by the European Medicines Agency (EMA) on January 11 of the same year. fosaprepitant.txt Last modified: 2024/06/07 02:55by 127.0.0.1